M
Medicus Pharma Ltd. (MDCX)
0.45
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.45
0.00 (0.00%)
Medicus Pharma Ltd., biotexnologiya/hayot haqidagi fanlar kompaniyasi, Qo'shma Shtatlarda terapevtik aktivlarni klinik rivojlantirish dasturlarini ishlab chiqishga qaratilgan. Kompaniya SKNJCT-003ni ishlab chiqmoqda, u terining bazal hujayrali karsinomasini davolash uchun 2-bosqich tadqiqotida. Medicus Pharma Ltd. Gorlin Sindromi Alyansi bilan Gorlin Sindromi Bemorlarida SKINJECTga kirish uchun strategik hamkorlikka ega. Kompaniya ilgari Interactive Capital Partners Corporation nomi bilan tanilgan va 2023 yil sentyabr oyida Medicus Pharma Ltd. nomini o'zgartirgan. Kompaniya 2008 yilda ro'yxatga olingan va shtab-kvartirasi Pensilvaniya shtatining Konshoxoken shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Edward J. Brennan Jr., F.A.C.S., M.D. | Chief Scientific Officer and Head of R&D Program |
| Dr. Faisal Mehmud M.D. | Chief Medical Officer |
| Dr. Raza Bokhari M.B.A., M.D. | CEO & Executive Chairman |
| Mr. Andrew Alasdair Smith | Chief Operating Officer |
| Ms. Anna Baran-Djokovic J.D. | Senior Vice President of Investor Relations |
| Ms. Maryann Adesso | Chief of Staff & Corporate Secretary |
| Ms. Viktoria Slepeniuk | Senior Vice President of Public Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-06 | 8-K | form8k.htm |
| 2026-01-30 | S-3 | forms3.htm |
| 2026-01-12 | DRS | filename1.htm |
| 2025-12-10 | DRS | filename1.htm |
| 2025-12-08 | 8-K | form8k.htm |
| 2025-12-01 | 253G2 | form253g2.htm |
| 2025-11-19 | S-1 | forms1.htm |
| 2025-11-17 | 253G2 | form253g2.htm |
| 2025-11-14 | 8-K | form8k.htm |
| 2025-10-17 | 8-K | form8k.htm |